Martha M. Rumore, PharmD, RPh, MS, LLM, Esq

Analyzing the patent and trademark challenges faced by 503A compounding pharmacies.

FDA seeks to reduce diversion of pharmaceutical products via sales by unlicensed distributers and tighten up the supply chain by vetting trading partners.